Off-the-shelf CD123 CAR-NK for R/R AML

Summary

This is a single-centre, single-arm, open-label, first-in-human (FIH) study to evaluate the safety, tolerability and preliminary efficacy of universal Off-the-shelf CAR-NK cells targeted CD123 (JD123 injection) in the treatment of refractory or relapsed CD123-positive acute myeloid leukemia (AML).

Timeline

Start

2023-12-30

Primary completion

2025-12-30

Completion

2025-12-30

Drugs

Indications